Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

The updated mRNA-1273.815 COVID-19 vaccine was significantly protective against hospitalization and medically attended outcomes among adults in the United States.

Vaccine hesitancy was rising even before COVID-19 emerged – but the pandemic exacerbated the trend. More kindergartners are ...

as her team is now interested in reducing the dosage to one. Further, The International Papillomavirus Society believes that the United States is on track to eliminate cervical cancer through ...

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top executives said. Moderna is currently in a late-stage trial for a vaccine for ...

BioNTech began working on a vaccine ... dose, they were already planning the Phase 3 trials to evaluate whether the vaccines were effective and safe. [What you need to know about the Moderna ...

About the vaccine, how it works, how it is given, ingredients, allergies, possible side effects, safety monitoring ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

In a 2021 case study, a single person with severe asthma experienced worsening symptoms following the second dose of the Pfizer ... Currently, the Moderna COVID-19 vaccine is only approved for ...

The two-dose immunization ... shows higher shares of vaccine-exempt students than North Texas counties since the 2013-14 school year. Here’s what that chart looks like for just kindergarteners ...

(Bloomberg) -- US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., people familiar with the matter said.